SHPH
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) Economic Moat Analysis (2026)
No material changes this month.
Intangible Assets
SHPH shows no evident filing-supported brand, patent, or regulatory asset that would let it command durable pricing power versus peers.
The absence of disclosed long-lived proprietary assets implies competitors can more easily match its offering, limiting margin durability relative to stronger-moat peers.
Negative ROIC and ROCE suggest any intangible advantage is not translating into economic returns, which is inconsistent with a durable asset-based moat.
Compared with peers that monetize protected IP or regulated franchises, SHPH appears structurally weaker because there is no visible evidence of exclusive customer demand or defensible IP.
Switching Costs
The available metrics do not indicate customer lock-in, so retention appears more dependent on price or convenience than on embedded workflows versus peers.
Negative invested-capital returns imply customers are not paying for a differentiated, hard-to-replace solution that would raise switching friction.
No evidence of contractual, technical, or data migration barriers is provided, which makes switching costs look materially lower than in peer businesses with integrated platforms.
Relative to peers with recurring enterprise relationships, SHPH does not show signs of high renewal stickiness or pricing power from switching frictions.
Network Effects
There is no evidence of a user, data, or marketplace flywheel that would make SHPH more valuable as adoption rises.
The provided financial metrics do not show the scale economics typically associated with network-driven retention or margin expansion.
Without observable ecosystem participation, SHPH lacks the peer-dependent demand loop that supports durable network effects.
Compared with platform peers, SHPH appears to have little or no structural advantage from cross-side or same-side network effects.
Cost Advantage
Negative ROIC and ROCE indicate SHPH is not converting capital into returns efficiently enough to suggest a durable unit-cost advantage versus peers.
The data do not show superior asset productivity or margin structure that would support a persistent cost edge.
A cash conversion cycle of -708 days is not, by itself, evidence of a moat and may reflect working-capital timing rather than structural cost leadership.
Relative to peers with scale purchasing power or process advantages, SHPH does not currently demonstrate a defensible cost advantage.
Efficient Scale
The available information does not indicate that SHPH operates in a market where one or a few firms can serve demand at materially lower cost than multiple rivals.
No evidence is provided that SHPH benefits from a protected niche, regulated capacity constraint, or natural monopoly-like structure.
Negative returns suggest any scale it has is not yet translating into durable operating leverage or peer-leading economics.
Compared with peers in efficient-scale markets, SHPH shows no clear sign of structural capacity scarcity or incumbent protection.
Overall Score
SHPH does not show evidence of a durable economic moat versus peers because the available filing-linked and financial data do not support pricing power, retention, or structural cost advantages, and negative returns indicate weak monetization of any potential advantage.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Shuttle Pharmaceuticals Holdings, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.
